Welcome to our dedicated page for CME Group SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
as the world's leading and most diverse derivatives marketplace, cme group (www.cmegroup.com) is where the world comes to manage risk. cme group exchanges offer the widest range of global benchmark products across all major asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, metals, weather and real estate. cme group brings buyers and sellers together through its cme globex® electronic trading platform and its trading facilities in new york and chicago. cme group also operates cme clearing, one of the world’s leading central counterparty clearing provider in the world, which offers clearing and settlement services for exchange-traded contracts, as well as for over-the-counter derivatives transactions through cme clearport®. these products and services ensure that businesses everywhere can substantially mitigate counterparty credit risk in both listed and over-the-counter derivatives markets.CME Group director Rahael Seifu reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted through the CME Group Director Stock Plan.
Following this transaction, Seifu now beneficially owns 4,094 shares directly. The filing indicates this was a planned compensation grant rather than an open market purchase.
Key Transaction Details:
- Transaction Type: Stock Award (Plan-Based)
- Ownership Type: Direct
- Role: Director
- Total Transaction Value: $145,251.96
CME Group director Patrick J. Mulchrone reported insider trading activity on June 25, 2025. Key details of the transaction include:
- Acquired 532 shares of Class A Common Stock at $273.03 per share through the CME Group Director Stock Plan
- Following the transaction, Mulchrone directly owns 28,485 shares
- Additionally holds 25,000 shares indirectly through spouse
The Form 4 filing indicates this was a planned acquisition under the company's director compensation program rather than an open market transaction. The filing was submitted by Jenelle Chalmers on behalf of Mulchrone on June 26, 2025, within the required reporting timeframe.
CME Group director Phyllis M. Lockett reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Lockett now beneficially owns 3,640 shares directly. The filing indicates this was a planned stock grant as part of director compensation rather than an open market purchase.
- Transaction Code: A (Grant/Award)
- Ownership Form: Direct (D)
- Filing Type: Form 4 (Statement of Changes in Beneficial Ownership)
- Total Transaction Value: Approximately $145,252
This insider transaction represents routine director compensation and does not indicate any unusual trading patterns or significant changes in ownership structure.
CME Group director Deborah J. Lucas reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Lucas now beneficially owns 3,888 shares directly. The filing indicates this was a routine director stock grant rather than an open market purchase.
Key Transaction Details:
- Transaction Type: Stock Award (Code A)
- Ownership Type: Direct
- Role: Director
- Total Transaction Value: $145,251.96
CME Group director Bryan T. Durkin reported the acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Durkin now beneficially owns 47,207 shares directly. The filing indicates this was a standard director compensation grant rather than an open market purchase.
Key Transaction Details:
- Transaction Type: Stock Award (Code A)
- Ownership Type: Direct
- Role: Director
- Total Value of Transaction: $145,251.96
CME Group director Daniel G. Kaye reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Kaye now beneficially owns 4,200 shares directly. The filing indicates this was a planned acquisition under the company's director compensation program rather than an open market purchase.
- Transaction Type: Stock Grant (Code A)
- Reporting Person Role: Director
- Ownership Form: Direct
- Filing was submitted by Jenelle Chalmers on behalf of Daniel G. Kaye
CME Group director Charles P. Carey reported insider trading activity on June 25, 2025. The transaction involved the acquisition of 879 Class A Common Stock shares at a price of $273.03 per share through a trust, granted pursuant to the CME Group Director Stock Plan.
Following the transaction, Carey's beneficial ownership consists of:
- 5,779 shares held indirectly through trust
- 185 shares held indirectly through firm
- 0.375 shares held indirectly through partnership
The Form 4 filing indicates this was a planned acquisition under the director compensation program rather than an open market transaction. No derivative securities were involved in this transaction.
CME Group director William W. Hobert reported insider trading activity on June 25, 2025. The transaction involved the acquisition of 879 shares of Class A Common Stock at a price of $273.03 per share through the CME Group Director Stock Plan.
Following the transaction, Hobert's holdings include:
- 86,598 shares held directly
- 40,000 shares held indirectly through his firm
The transaction was executed pursuant to the company's Director Stock Plan, as amended and restated. The Form 4 was filed on behalf of Hobert by Jenelle Chalmers on June 26, 2025, within the required reporting timeframe.
CME Group director Martin J. Gepsman reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Gepsman now beneficially owns a total of 25,299 shares directly. The filing indicates this was a standard director compensation grant rather than an open market purchase.
- Transaction Type: Stock Award (Code A)
- Ownership Form: Direct
- Filing Status: Individual filing
- Role: Director (non-employee)
This insider transaction represents routine director compensation and aligns with standard corporate governance practices for board member equity compensation.
CME Group Inc. (CME) filed a Form 4 disclosing that Director Howard J. Siegel acquired 879 shares of Class A common stock on 06/25/2025 at $273.03 per share under the company’s Director Stock Plan. Following the purchase, Siegel holds 47,791 shares directly and 21,873 shares indirectly through a trust. No derivative transactions or share dispositions were reported.
FAQ
What is the current stock price of CME Group (CME)?
What is the market cap of CME Group (CME)?
